📈 நேரலை சந்தை கண்காணிப்பு

NSE மற்றும் BSE-யின் ஒவ்வொரு கார்ப்பரேட் அறிவிப்பும், AI-யால் சில நிமிடங்களில் படிக்கப்பட்டு விளக்கப்படுகிறது — தாக்கம், முக்கிய புள்ளிவிவரங்கள், குறுகிய/நீண்டகாலப் பார்வை, கவனிக்க வேண்டியவை.

நேரலை இன்று 1107 பகுப்பாய்வு செய்யப்பட்டது
பின்தொடர்Telegram
1107
இன்று
169,808
இதுவரை பகுப்பாய்வு செய்யப்பட்டவை
50,192
நேர்மறை
8,697
எதிர்மறை
101,061
நடுநிலை
9,790
கண்காணி
குறிப்பு: இவை NSE பொது அறிக்கைகளின் AI-உருவாக்கிய, கல்வி நோக்கச் சுருக்கங்கள் — ஒவ்வொரு ஆவணத்தையும் ஆதாரமாகக் கொண்டவை, ஆனால் முதலீட்டு ஆலோசனை அல்ல, மேலும் முழுமையற்றதாகவும் இருக்கலாம். அசல் அறிக்கையுடன் சரிபார்க்கவும், செயல்படுவதற்கு முன் SEBI-பதிவு பெற்ற முதலீட்டு ஆலோசகரை அணுகவும்.
அழி
754 அறிவிப்புகள் பொருந்தும் தாக்கம் 5+ Symbol: BI
கண்காணிப்பு தாக்கம் 8/10 M&A

IDBI Bank Clarifies on Divestment News; Confirms 60.72% Stake Sale Process is Ongoing

IDBI Bank has clarified to the exchanges that the strategic disinvestment process is a confidential matter handled by the Government of India and DIPAM. The bank reiterated that the proposed sale involves a 60.72% stake, comprising 30.48% from the Government and 30.24% from LIC. While the bank cannot confirm or deny recent media reports regarding the Finance Minister's comments, it confirmed that the competitive bidding process is governed by GOI guidelines. The bank has already received SEBI approvals for re-classifying promoters as public shareholders upon completion of the sale.

நடுநிலை தாக்கம் 7/10 BOARD_MEETING

Biocon Board Meeting on May 07 to Approve Q4 FY26 Results and Consider Dividend

Biocon Limited has scheduled its Board Meeting for May 07, 2026, to approve the audited standalone and consolidated financial results for the quarter and full year ended March 31, 2026. The company will also consider the recommendation of a dividend for the fiscal year during this meeting. An earnings conference call for analysts and investors is set for May 08, 2026, at 9:00 AM IST. The trading window for the company's securities remains closed from April 01, 2026, to May 09, 2026.

நேர்மறை தாக்கம் 7/10 விரிவாக்கம்

Birla Corp Starts Coal Mining at Bikram Mine; Corrects Capacity to 0.36 MTPA

Birla Corporation has officially commenced coal mining operations at its Bikram Coal Mine located in Shahdol, Madhya Pradesh. The company issued a corrigendum to clarify that the peak rated capacity of the mine is 0.36 million tonnes per annum (MTPA), correcting a previous error. The total extractable reserves for this mine are estimated at 9.44 million tonnes. This development is a significant step toward achieving fuel self-sufficiency and reducing power and fuel costs for its cement operations.

நேர்மறை தாக்கம் 8/10 விரிவாக்கம்

Birla Corp Commences Mining at Bikram Coal Mine with 9.44 MT Annual Capacity

Birla Corporation Limited has officially commenced mining operations at its Bikram Coal Mine located in Shahdol, Madhya Pradesh, as of April 23, 2026. The mine features a substantial annual production capacity of 9.44 million tonnes of thermal coal. This operational milestone is expected to significantly enhance the company's fuel self-sufficiency for its cement manufacturing units. By securing a captive coal source, the company aims to reduce its dependence on external fuel markets and stabilize its power and fuel costs.

கண்காணிப்பு தாக்கம் 8/10 நிர்வாகம்

Bikaji Foods Announces Demise of Founder and Chairman Shri Shiv Ratan Agarwal

Bikaji Foods International Limited has announced the passing of its Founder, Chairman, and Whole-Time Director, Shri Shiv Ratan Agarwal, on April 23, 2026. With over 50 years of industry experience, he was the primary architect in building Bikaji into India's third-largest ethnic snacks company. While the loss of a visionary founder is significant, the company is currently the second fastest-growing player in the organized snacks market with a professional management structure in place. Investors should monitor the transition of leadership and the official appointment of a new Chairman.

📊 கடந்த 7 நாட்கள் — உணர்வு அடிப்படையில் பகுப்பாய்வு செய்யப்பட்ட அறிவிப்புகள்

நேர்மறைஎதிர்மறைநடுநிலைகவனம்
நேர்மறை தாக்கம் 8/10 நிதி முடிவுகள்

SBI Life FY26 Results: PAT at ₹24.7B, VoNB Margin 27.5%, AUM nears ₹4.9 Trillion

SBI Life Insurance reported a steady performance for FY26, with Profit After Tax (PAT) reaching ₹24.7 billion and Value of New Business (VoNB) at ₹66.7 billion. The company maintained a healthy VoNB margin of 27.5% and saw its Embedded Value grow to ₹807.9 billion, reflecting a 19.7% Operating ROEV. Assets Under Management (AUM) grew 9% year-on-year to ₹4,872 billion, supported by a strong solvency ratio of 1.90x. The distribution network remains a key strength, with over 27,000 bank branches and a 99.7% digital adoption rate for individual applications.

நேர்மறை தாக்கம் 6/10 நிர்வாகம்

IFB Industries Shareholders Approve Board Appointments with Over 99% Majority

IFB Industries Limited has announced the successful passage of six resolutions via postal ballot, all receiving overwhelming shareholder support exceeding 99.8%. Key approvals include the re-appointment of Mrs. Sreedevi Pillai and the new appointments of Mr. Saurav Adhikari, Mr. Subir Chakraborty, and Mr. Tarun Kumar Daga as Independent Directors. The voting saw a high turnout of 81.02% of total shares, driven largely by 100% participation from the promoter group. These results ensure board stability and compliance with corporate governance norms for the upcoming financial periods.

நேர்மறை தாக்கம் 6/10 நிர்வாகம்

OnMobile Shareholders Approve Manoranjan Mohapatra as Independent Director with 99.99% Votes

OnMobile Global Limited shareholders have officially approved the appointment of Manoranjan Mohapatra as a Non-Executive Independent Director through a special resolution. The voting results showed overwhelming support, with 99.99% of the 51.46 million votes cast in favor of the appointment. The total votes polled represented approximately 48.41% of the company's total share capital. This move is aimed at enhancing the board's independent oversight and corporate governance standards.

நேர்மறை தாக்கம் 8/10 நிதி முடிவுகள்

SBI Life FY26 Net Profit Rises to ₹2,470 Cr; Gross Premium Income Grows 19% YoY

SBI Life Insurance reported a steady financial performance for FY26, with net profit increasing to ₹2,470.30 crore from ₹2,413.30 crore in FY25. The company achieved robust top-line growth, with Gross Premium Income rising 18.9% YoY to ₹99,955.92 crore. While Q4 FY26 net profit saw a marginal decline to ₹804.64 crore compared to ₹813.51 crore in the year-ago period, operational metrics remained healthy. The 13th-month persistency ratio improved to 87.94%, and the solvency ratio remains strong at 1.90.

எதிர்மறை தாக்கம் 6/10 ஒழுங்குமுறை

Rubicon Research Receives ₹17.25 Crore Income Tax Demand for AY 2023-24

Rubicon Research Limited has received an assessment order from the Income Tax Department for the Assessment Year 2023-24. The order includes additions and disallowances totaling ₹20.68 crore, primarily related to Arm's Length Pricing adjustments on international transactions. This has resulted in a total tax demand of ₹17.25 crore. The company has also been issued a show-cause notice for penalty proceedings but intends to contest the demand through an appeal, asserting a strong legal position.

எதிர்மறை தாக்கம் 8/10 சட்டம்

BIL Vyapar Limited Schedules 8th Committee of Creditors Meeting for April 22, 2026

BIL Vyapar Limited, formerly known as Binani Industries Limited, has announced the 8th meeting of its Committee of Creditors (CoC) to be held on April 22, 2026. The company is currently undergoing the Corporate Insolvency Resolution Process (CIRP) under the Insolvency and Bankruptcy Code. This meeting is a critical step in the ongoing restructuring process to address the company's debt obligations. Investors should remain aware that the company's management is currently overseen by a Resolution Professional.

நேர்மறை தாக்கம் 7/10 ஒழுங்குமுறை

Biocon Receives Health Canada Approval for Denosumab Biosimilars Bosaya and Vevzuo

Biocon has secured Health Canada approval for Bosaya and Vevzuo, biosimilars to the blockbuster drugs Prolia and Xgeva respectively. These approvals target a significant market in Canada, potentially benefiting over 2 million adults with osteoporosis and hundreds of patients with bone metastasis. The products are approved in standard dosages: Bosaya as a 60 mg/mL prefilled syringe and Vevzuo as a 120 mg/1.7 mL vial. This milestone expands Biocon's global biosimilar portfolio, which now includes 12 commercialized products and a pipeline of over 20 assets.

நேர்மறை தாக்கம் 7/10 விரிவாக்கம்

OnMobile Signs 3-Year Strategic Supply Agreement with Flipkart for Gaming Hardware Distribution

OnMobile Global Limited has entered into a three-year wholesale supply agreement with Flipkart India Private Limited, effective April 20, 2026. This partnership aims to distribute OnMobile's upcoming gaming hardware and digital services ecosystem across Flipkart's extensive e-commerce platform. The deal provides OnMobile with significant reach into the domestic gaming consumer segment through one of India's largest retail channels. Financial consideration will be determined per purchase order, making the immediate revenue impact dependent on order volumes.

நேர்மறை தாக்கம் 6/10 நிர்வாகம்

Aditya Birla Money Appoints Amit Lahoti as Head of Equity Research

Aditya Birla Money Limited has appointed Mr. Amit Lahoti as the Head of Equity Research and a Senior Management Personnel, effective April 17, 2026. Mr. Lahoti brings over 15 years of specialized experience in the Metals and Mining sectors, having previously held significant roles at Emkay Global and Citigroup. This appointment is intended to strengthen the firm's core research capabilities and enhance investor engagement. The decision follows a recommendation from the Nomination and Remuneration Committee and was approved by the Board of Directors.

நேர்மறை தாக்கம் 7/10 நிதி முடிவுகள்

Aditya Birla Money Q4 PAT Surges 255% YoY to ₹18.74 Cr; FY26 Revenue at ₹468.6 Cr

Aditya Birla Money reported a robust Q4 FY26 with Profit After Tax (PAT) jumping 255% YoY to ₹18.74 crore, driven by strong growth in the broking and wholesale debt market segments. Quarterly revenue from operations grew 30.5% YoY to ₹129.80 crore. While the quarterly performance was stellar, the full-year FY26 PAT saw a decline to ₹54.72 crore from ₹74.19 crore in FY25, largely due to higher finance costs and a one-time statutory impact of ₹3.13 crore related to new labour codes. The company's net worth strengthened to ₹300.25 crore as of March 31, 2026.

நேர்மறை தாக்கம் 7/10 விரிவாக்கம்

Bigbloc Construction Subsidiary Starts Trial Production at Umargaon Chemicals Plant

Bigbloc Construction Limited's wholly-owned subsidiary, Bigbloc Building Elements Private Limited, has successfully commenced trial production at its new Umargaon facility. This state-of-the-art plant is dedicated to construction chemicals, representing a strategic diversification of the company's product portfolio. The move aligns with the group's long-term strategy to expand its footprint in the construction materials sector. Investors should view this as a key step toward operationalizing new revenue streams.

நேர்மறை தாக்கம் 9/10 M&A

Rubicon Research Acquires 85% Stake in Arinna Lifesciences for INR 175.92 Crores

Rubicon Research has announced the acquisition of an 85% equity stake in Arinna Lifesciences, marking its entry into the Indian domestic CNS formulations market. The transaction values Arinna at an enterprise value of INR 200 Crores, with Rubicon paying approximately INR 175.92 Crores for the majority stake. Arinna is a specialist in Central Nervous System (CNS) therapies with over 60 brands and a network of 4,000+ prescribers. For the nine months ended December 2025, Arinna reported a provisional revenue of INR 56.7 Crores and an EBITDA of INR 9.5 Crores.

நடுநிலை தாக்கம் 6/10 M&A

Triveni Turbine Merges South African Subsidiaries with Combined Turnover of Rs 169 Cr

Triveni Turbine has successfully merged its two South African step-down subsidiaries, TSE Engineering and Triveni Turbines Africa, effective April 1, 2026. The merger consolidates operations that had a combined FY25 turnover of approximately Rs 169 crore, with TTAPL contributing Rs 119 crore and TSE contributing Rs 50 crore. This internal restructuring is designed to simplify the group's corporate structure and enhance operational efficiencies in the African market. As both entities were 100% owned, there is no change in the parent company's shareholding pattern or cash outflow.

எதிர்மறை தாக்கம் 8/10 சட்டம்

BIL Vyapar Limited Schedules 7th Committee of Creditors Meeting for April 13, 2026

BIL Vyapar Limited, formerly known as Binani Industries Limited, has announced the 7th meeting of its Committee of Creditors (CoC) scheduled for April 13, 2026. The company is currently undergoing the Corporate Insolvency Resolution Process (CIRP) under the Insolvency and Bankruptcy Code. This meeting is a critical step in determining the future of the company, including potential resolution plans or liquidation. As the company is under CIRP, the management is currently overseen by a Resolution Professional, and the powers of the Board of Directors remain suspended.

நேர்மறை தாக்கம் 6/10 வழக்கமானது

Panacea Biotec Secures INR 20.79 Crore Vaccine Supply Order from CMSS

Panacea Biotec Limited has received a Letter of Award from the Central Medical Services Society (CMSS), under the Ministry of Health and Family Welfare, for the supply of Diphtheria and Tetanus (Td) vaccines. The total value of the contract is INR 20.79 Crore. The supply is scheduled to be executed in multiple tranches starting from September/October 2026 and concluding by November/December 2028. This domestic order provides long-term revenue visibility for the company's vaccine segment.

⚠️ இந்தத் தளம் எவ்வாறு உருவாக்கப்படுகிறது: சந்தைத் தரவுப் பக்கங்கள் NSE/BSE வெளியீடுகள் மற்றும் நிறுவனங்களின் தாக்கல்களிலிருந்து தானாகக் கணக்கிடப்படுகின்றன; செய்திக் கட்டுரைகளும் அறிவிப்புப் பகுப்பாய்வுகளும் AI உதவியுடன் எழுதப்படுகின்றன, மனித மேற்பார்வையுடன்: AI உருவாக்குவதை எங்கள் ஆசிரியர்கள் மதிப்பாய்வு செய்கின்றனர். இரண்டிலும் பிழைகள் இருக்கலாம். எந்தவொரு முதலீட்டு முடிவுக்கு முன்பும் அசல் மூலங்களில் சரிபார்க்கவும். முதலீட்டு ஆலோசனை அல்ல; Flash Finance SEBI-பதிவு பெற்றது அல்ல. நாங்கள் AI-ஐ எவ்வாறு பயன்படுத்துகிறோம்